Associated tags: IL7, TSLP, IL33, Type 1 diabetes, Biotechnology, Health, Inflammation, Pharmaceutical, Clinical Trials, Research, Science, Pharmaceutical industry, Patient
Locations: UNITED KINGDOM, NEW YORK, US, VIRGINIA, NY, UNITED STATES, NORTH AMERICA, NEVADA, RUSSELL, BIO
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor conferences in June.
- Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in one-on-one meetings on Thursday, June 6, 2024, in New York, NY.
- Details: Robert Lisicki, Chief Executive Officer, will participate in a “Novel Immunological Mechanisms for Dermatological Disorders” panel discussion and one-on-one meetings on Monday, June 24, 2024, in New York, NY.
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Ulcerative colitis,
Systemic scleroderma,
Alopecia areata,
HS,
Research and development,
Administration,
Patient,
TSLP,
Record,
Inflammation,
Senior,
Atopic dermatitis,
Asthma,
Autoimmunity,
G&A,
Chronic obstructive pulmonary disease,
Pharmaceutical industry Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its first quarter 2024 financial results, and recent business highlights.
- "Our recent financial and business highlights demonstrate how we continue to strengthen the company for future success.
- The private placement by leading life sciences investors emphasizes the confidence in our pipeline of novel, dual-pathway antibodies for autoimmune and inflammatory diseases,” stated Robert Lisicki, CEO of Zura Bio.
- Zura Bio anticipates that with the recent private placement factored in, its cash and cash equivalents are sufficient to fund planned operations through 2027.
Professional Services,
Health,
Finance,
Clinical Trials,
Pharmaceutical,
Biotechnology,
Sale,
Prospectus,
Systemic scleroderma,
HS,
Private,
Hidradenitis suppurativa,
Guggenheim Partners,
Cantor,
Inflammation,
Placement,
Autoimmunity,
Security (finance) Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”).
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”).
- The Private Placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).
- The private placement is expected to close on April 22, 2024, subject to satisfaction of customary closing conditions.
- Piper Sandler, Guggenheim Securities, and Cantor served as lead placement agents for the Private Placement.
Biotechnology,
Pharmaceutical,
Health,
Clinical Trials,
Partnership,
Drug development,
Multimedia,
Autoimmunity,
Autoimmune disease,
Inflammation,
Management Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.
- The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process with Founding CEO, Dr. Someit Sidhu.
- "With a successful track record in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company.
- On behalf of the board, I would like to welcome Robert,” stated Amit Munshi, Chairman of Zura Bio Board of Directors.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
IL-17A,
Administration,
Ulcerative colitis,
Congress,
Thymic stromal lymphopoietin,
Atopic dermatitis,
Alopecia areata,
Inflammation,
Chronic obstructive pulmonary disease,
Allergy,
TSLP,
BCA,
CMC,
G&A,
Interleukin 7,
Benaroya Research Institute,
Business analyst,
Abstract,
Asthma,
IL-7,
Research and development,
Drug development,
Senior management,
BAFF,
Eli Lilly and Company,
Translational medicine,
Autoimmunity,
Management Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
- The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
- Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
- Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Translational medicine,
Inflammation,
Congress,
EST,
Business development,
News Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate in three conferences in March.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate in three conferences in March.
- He will be joined by Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, for investor meetings.
- Details: Kiran Nistala, M.D., Ph.D., Chief Medical Officer and Head of Development, and other members of the Zura Bio Development team will attend the Congress from March 14 - 16, 2024, in Prague, Czech Republic.
- Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors & Media section of the Zura Bio website.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
CO,
TSLP,
EST,
Inflammation,
Translational medicine,
News,
Pharmaceutical industry Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in February.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate at several upcoming conferences in February.
- Details: Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine, will participate in 1x1 investor meetings from February 5 - 8, 2024, in Vail, CO.
- Details: Robert Lisicki, President and Chief Operating Officer, will participate in a company presentation and investor 1x1 meetings on February 7 – 8, 2024, in New York, NY.
- Links for live webcasts and replays, if available, will be posted on the News & Events page in the Investors section of the Zura Bio website.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
General Health,
Health,
Clinical Trials,
Marketing,
Arena,
Pfizer,
Autoimmune disease,
GSK plc,
Dermatology,
Multimedia,
Johnson & Johnson,
Amgen,
AstraZeneca,
Child,
Rheumatology,
Arena Pharmaceuticals,
Protocol,
Trust,
Lupus,
CCO,
University,
Wellcome Trust,
Doctor of Philosophy,
Therapy,
Senior,
State,
University College London,
Great Ormond Street Hospital,
Inflammation,
Myositis,
MBBS,
Regeneron Pharmaceuticals,
Growth,
Mergers and acquisitions,
Patient,
State university system,
Economics,
Scleroderma,
Management Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.
Key Points:
- Mr. Lisicki will be responsible for developing and driving the business plan and strategic initiatives as Zura Bio builds a leading immunology company.
- Mr. Lisicki and Dr. Nistala have successfully worked on or led in the development of multiple drugs within the auto-immune therapeutic area.
- These executives position Zura Bio to deliver on the promise of their innovative medicines for patients in need of better clinical outcomes.
- View the full release here: https://www.businesswire.com/news/home/20240108851979/en/
“I am very pleased to welcome Rob and Kiran to Zura Bio as members of the Executive Team.
Retrieved on:
Wednesday, January 3, 2024
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will present at two upcoming conferences in January.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will present at two upcoming conferences in January.
- A live webcast and replay of the presentation from the 42nd Annual J.P. Morgan Healthcare Conference will be available via the News & Events page in the Investors section of the Zura Bio website.
- The presentation will be archived on the website for at least 30 days following the event.
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Rheumatism,
IL-7,
Congress,
WAC,
Inflammation,
World Allergy Organization,
Abstract,
Biology,
Research fellow,
TSLP,
Vaccine,
Forestry Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.
Key Points:
- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand.
- “Introducing Zura Bio’s ZB-168 and ZB-880 at World Allergy Congress is an opportunity to share the unique science behind these assets.
- ZB-168 uniquely inhibits both IL-7 and TSLP, while ZB-880 prevents IL-33 mediated-activation of ST2-dependent and independent inflammation.
- “We believe these could have applicability in the dermatological, rheumatological, gastrointestinal and respiratory spaces, and we are very excited about taking these development programs forward.”
